Freddy A. Jimenez directly sold 4,166 shares for a transaction value of $121,210 on Dec. 4, 2025.
This transaction represented 11.92% of his direct holdings at the time, reducing his direct stake from 34,962 to 30,796 shares.
The sale was executed entirely in direct ownership, with no involvement of indirect entities or derivative securities.
On Dec. 4, 2025, Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (NASDAQ:CLDX), executed an open-market sale of 4,166 insider shares. See SEC Form 4 filing.
Metric | Value |
|---|---|
Shares sold (direct) | 4,166 |
Transaction value | $121,210 |
Post-transaction shares (direct) | 30,796 |
Post-transaction value (direct ownership) | $895,856 |
Transaction value based on SEC Form 4 reported price ($29.09); post-transaction value based on Dec. 4, 2025 market close ($29.09).
How does the size of this sale compare to Jimenez’s historical selling activity?
This sale of 4,166 shares is larger than his only other recent open-market sale (771 shares on Aug. 13, 2025) and exceeds the recent median sell size of 2,468 shares.What proportion of Jimenez’s total equity interest was affected by this transaction?
The sale reduced his direct ownership by 11.92%, leaving him with 30,796 shares and no indirect holdings as of Dec. 8, 2025.
Metric | Value |
|---|---|
Market capitalization | $1.82 Billion |
Revenue (TTM) | $2.60 million |
Net income (TTM) | -$224.53 million |
*1-year price change | -0.26% |
* 1-year price change calculated using Jan. 12, 2025 as the reference date.
Celldex Therapeutics develops therapeutic antibodies, with lead clinical programs targeting inflammatory diseases and oncology indications.
The company operates uses a research-driven biopharmaceutical model, focused on research collaboration and license agreements.
It targets healthcare providers, research institutions, and pharmaceutical partners focused on innovative treatments for immune-mediated diseases and cancer.
Jimenez wasn’t the only SVP conducting insider transactions near the beginning of 2026. On Dec. 15, 2025, SVP & CBO Pepin Ronald acquired 19,333 shares by exercising two previously granted stock options. One option allowed him to purchase 8,333 shares at a price of $9.02, while the other provided him with 11,000 shares at an exercise price of $2.78. The total value of the acquisitions was $105,744.
Then on Jan. 2, 2026, Martin Samuel Bates, SVP and CFO, also acquired shares by exercising an option. He acquired 4,817 shares at a price of $10.38, worth $50,000. It’s unclear why both Ronald and Bates waited years to exercise their options, even though they reached their strike prices years earlier.
